Your browser doesn't support javascript.
loading
Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).
Gulick, Roy M; Wilkin, Timothy J; Chen, Ying Q; Landovitz, Raphael J; Amico, K Rivet; Young, Alicia M; Richardson, Paul; Marzinke, Mark A; Hendrix, Craig W; Eshleman, Susan H; McGowan, Ian; Cottle, Leslie M; Andrade, Adriana; Marcus, Cheryl; Klingman, Karin L; Chege, Wairimu; Rinehart, Alex R; Rooney, James F; Andrew, Philip; Salata, Robert A; Magnus, Manya; Farley, Jason E; Liu, Albert; Frank, Ian; Ho, Ken; Santana, Jorge; Stekler, Joanne D; McCauley, Marybeth; Mayer, Kenneth H.
Afiliação
  • Gulick RM; Department of Medicine, Weill Cornell Medicine, New York.
  • Wilkin TJ; Department of Medicine, Weill Cornell Medicine, New York.
  • Chen YQ; Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center.
  • Landovitz RJ; Department of Medicine, University of California, Los Angeles.
  • Amico KR; Department of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor.
  • Young AM; Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center.
  • Richardson P; Department of Pathology.
  • Marzinke MA; Department of Medicine, Johns Hopkins University School of Medicine.
  • Hendrix CW; Department of Medicine, Johns Hopkins University School of Medicine.
  • Eshleman SH; Department of Pathology.
  • McGowan I; Department of Medicine, University of Pittsburgh School of Medicine.
  • Cottle LM; Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center.
  • Andrade A; Department of Medicine, Johns Hopkins University School of Medicine.
  • Marcus C; Department of Medicine, University of North Carolina, Chapel Hill.
  • Klingman KL; HIV Research Branch.
  • Chege W; Clinical Prevention Research Branch, Prevention Sciences Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
  • Rinehart AR; ViiV Healthcare.
  • Rooney JF; Gilead Sciences, Foster City.
  • Andrew P; FHI 360, Durham, North Carolina.
  • Salata RA; Department of Medicine, Case Western Reserve University, Cleveland, Ohio.
  • Magnus M; Department of Epidemiology and Biostatistics, Milken Institute School of Public Health, George Washington University.
  • Farley JE; Johns Hopkins University School of Nursing, Baltimore.
  • Liu A; Bridge HIV, San Francisco Department of Public Health, California.
  • Frank I; Department of Medicine, Perelman School of Medicine of the University of Pennsylvania, Philadelphia.
  • Ho K; Department of Medicine, University of Pittsburgh School of Medicine.
  • Santana J; Department of Medicine, University of Puerto Rico School of Medicine, San Juan.
  • Stekler JD; Department of Medicine, University of Washington, Seattle.
  • McCauley M; FHI 360, Washington, DC.
  • Mayer KH; Fenway Health, Department of Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, Massachusetts.
J Infect Dis ; 215(2): 238-246, 2017 Jan 15.
Article em En | MEDLINE | ID: mdl-27811319

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Triazóis / Infecções por HIV / Transmissão de Doença Infecciosa / Cicloexanos / Antagonistas dos Receptores CCR5 / Profilaxia Pré-Exposição Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Triazóis / Infecções por HIV / Transmissão de Doença Infecciosa / Cicloexanos / Antagonistas dos Receptores CCR5 / Profilaxia Pré-Exposição Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article